Diabetic Foot Medical Services in China

Diabetic foot is a serious, limb-threatening complication of diabetes mellitus characterized by infection, ulceration, and/or deep tissue destruction in the foot, often occurring in the context of peripheral neuropathy and/or peripheral artery disease. It arises from a complex interplay of metabolic, vascular, neurological, and biomechanical abnormalities. Chronically elevated blood glucose levels damage peripheral nerves (causing sensory, motor, and autonomic neuropathy), impairing protective sensation and foot muscle function—leading to unrecognized trauma and abnormal pressure distribution. Concurrently, hyperglycemia accelerates atherosclerosis and microvascular dysfunction, reducing blood flow to the feet and compromising wound healing and immune defense. Infection—often polymicrobial—can rapidly progress from superficial cellulitis to osteomyelitis or necrotizing fasciitis if untreated. Epidemiologically, diabetic foot ulcers affect approximately 15–25% of people with diabetes over their lifetime; globally, one lower-limb amputation occurs every 30 seconds due to diabetes-related complications. In China, prevalence is rising in parallel with the national diabetes epidemic—estimated at over 140 million adults living with diabetes—and diabetic foot accounts for >60% of non-traumatic lower-limb amputations in endocrinology departments. Key modifiable risk factors include poor glycemic control (HbA1c >8%), smoking, uncontrolled hypertension, dyslipidemia, history of prior foot ulcer or amputation, visual impairment, renal insufficiency, and inadequate footwear or foot hygiene. Non-modifiable risks include longer diabetes duration (>10 years), older age, male sex, and certain genetic predispositions. Beyond physical morbidity, diabetic foot profoundly impairs quality of life: patients report severe pain, mobility limitations, social isolation, depression, anxiety, loss of employment, and caregiver burden. Chronic wounds often necessitate prolonged offloading, frequent clinic visits, and hospitalizations—disrupting daily routines and eroding independence. Psychological distress correlates strongly with ulcer recurrence and delayed healing. Early detection through structured foot screening (monofilament testing, Doppler assessment, dermatological inspection) and multidisciplinary intervention—including endocrinologists, podiatrists, vascular surgeons, infectious disease specialists, and wound care nurses—is critical to prevent progression and preserve limb and life.

Diabetic foot is a serious, limb-threatening complication of diabetes mellitus, characterized by infection, ulceration, and/or deep tissue destruction, often occurring in the setting of peripheral neuropathy and/or peripheral artery disease (PAD). Effective management requires a multidisciplinary approach coordinated primarily by endocrinology, podiatry, vascular surgery, infectious disease, and wound care specialists. Early recognition and intervention are critical to prevent progression to osteomyelitis, sepsis, or non-traumatic amputation.

Conservative treatment forms the cornerstone of diabetic foot management, especially for non-infected, superficial ulcers without ischemia. It begins with strict glycemic control—targeting HbA1c ≤7.0% (53 mmol/mol) in most adults, individualized per patient comorbidities and life expectancy—to mitigate neuropathic progression and impair wound healing. Offloading is mandatory: total contact casting (TCC) remains the gold standard for plantar neuropathic ulcers, reducing peak plantar pressure by up to 90% and accelerating healing rates by 2–3-fold compared to therapeutic footwear alone. Alternatives include removable cast walkers, custom-molded diabetic shoes with pressure-relieving insoles, and felted foam dressings for localized offloading. Comprehensive foot hygiene education—including daily visual inspection (using mirrors if needed), moisturizing dry skin (avoiding interdigital application), and proper nail trimming—is essential. Regular podiatric debridement of hyperkeratotic tissue and nonviable wound margins promotes granulation and reduces bacterial bioburden; sharp debridement should be performed every 1–2 weeks until healthy tissue is exposed.

Pharmacologic therapy is tailored to the clinical phenotype. For infected ulcers, empiric antibiotic selection follows IDSA/ISH guidelines: mild infections (e.g., cellulitis <2 cm without systemic signs) may be treated with oral agents such as amoxicillin-clavulanate or clindamycin plus ciprofloxacin; moderate-to-severe infections (systemic toxicity, deep space involvement, or suspected osteomyelitis) require IV antibiotics—common regimens include piperacillin-tazobactam or vancomycin plus ceftazidime, adjusted based on culture and sensitivity results from deep tissue or bone biopsy (not swab). Adjunctive therapies include ACE inhibitors or ARBs for renoprotection and cardiovascular risk reduction, statins for lipid management, and low-dose aspirin in select high-risk patients. Emerging evidence supports adjunctive use of topical growth factors (e.g., recombinant human platelet-derived growth factor-BB, becaplermin) in neuropathic ulcers refractory to standard care, though cost-effectiveness remains debated. SGLT2 inhibitors and GLP-1 receptor agonists are increasingly favored for glycemic control due to their cardio- and renoprotective benefits, which indirectly support foot health.

Surgical intervention is indicated when conservative measures fail or when anatomical pathology demands correction. Revascularization—either endovascular (angioplasty/stenting) or surgical bypass—is urgent in patients with ischemic ulcers and hemodynamically significant PAD (e.g., ankle-brachial index <0.5, toe systolic pressure <30 mmHg, or transcutaneous oxygen pressure <25 mmHg). Endovascular approaches dominate current practice due to lower perioperative morbidity, particularly in frail, elderly, or multi-morbid patients. Surgical debridement becomes necessary for extensive necrosis, abscess formation, or suspected osteomyelitis; intraoperative bone biopsy is mandatory for definitive diagnosis. Limited digital or transmetatarsal amputation preserves functional ambulation and is preferred over below-knee amputation whenever feasible. In select cases, tendon lengthening (e.g., Achilles tenotomy) corrects biomechanical deformities contributing to recurrent ulceration. Advanced reconstructive options—including free or pedicled flaps—may be considered at tertiary centers for complex soft-tissue defects after infection control and revascularization.

Treatment in China offers distinct advantages rooted in integrated healthcare infrastructure and innovation. First, China’s national diabetic foot prevention network—established under the Chinese Diabetes Society—standardizes screening protocols across >2,000 designated centers, enabling early detection via monofilament testing, Doppler ultrasound, and thermal imaging. Second, rapid adoption of minimally invasive endovascular techniques, supported by domestically manufactured stents and drug-coated balloons, has improved limb salvage rates—recent multicenter data report 1-year major amputation-free survival exceeding 85% in revascularized cohorts. Third, China leads globally in AI-assisted wound assessment: FDA-cleared platforms like WoundVision® and domestic systems (e.g., DeepWound AI) analyze high-resolution images to quantify ulcer area, depth, and tissue composition, guiding timely escalation of care. Fourth, traditional Chinese medicine (TCM) integration—under rigorous evidence-based frameworks—includes topical herbal formulations (e.g., Huangbai-Chuanxiong decoction gels) shown in RCTs to reduce inflammatory cytokines (IL-6, TNF-α) and accelerate epithelialization when combined with standard care. Finally, centralized national registries (e.g., China Diabetic Foot Registry) facilitate real-world outcome tracking and quality improvement initiatives.

Recovery and long-term prevention hinge on sustained self-management and structured follow-up. Patients must maintain HbA1c <7.5% (58 mmol/mol) post-healing, with quarterly foot examinations by trained endocrinologists or podiatrists. Custom orthotics and annual footwear assessments prevent recurrence—studies show recurrence rates drop from 40% to <15% with consistent offloading adherence. Smoking cessation counseling is non-negotiable, given its synergistic effect on microvascular dysfunction. Nutritional optimization—including adequate protein intake (1.2–1.5 g/kg/day) and micronutrient repletion (vitamin D, zinc, B12)—supports collagen synthesis and immune function. Psychological support is integral: depression affects ~30% of diabetic foot patients and correlates strongly with poor adherence and delayed healing. Telemedicine-enabled remote monitoring—now reimbursed under China’s National Health Insurance—allows weekly photo uploads and virtual consultations, reducing outpatient burden while maintaining surveillance intensity. Ultimately, diabetic foot is preventable—not inevitable—and success depends less on any single modality than on systematic, patient-centered, and perpetually vigilant care.